BIO-TECHNE Corp vs United Microelectronics Corp — how do they compare? BIO-TECHNE Corp trades at $72.16 (market cap $11.24B), while United Microelectronics Corp trades at $18.99 (market cap $47.80B). The key difference: United Microelectronics Corp is far larger — about 4.3× BIO-TECHNE Corp's market cap, and United Microelectronics Corp pays the higher dividend (2.13%). Which is the better fit depends on your goals.
| TECH | UMC | |
|---|---|---|
Market Cap | $11.24B | $47.80B |
Sector | Health | Technology |
52-Week High | $72.29 | $28.02 |
52-Week Low | $43.31 | $6.58 |
Enterprise Value | $11.32B | $44.92B |
Dividend Yield | 0.44% | 2.13% |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
UMC trades at $18.72, down 2.5% today, amid a bearish technical signal with key resistance at $19. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.54 vs. $0.16 expected, and announced fab expansions in Singapore and Taiwan to meet AI-driven demand. Revenue growth is projected to rise to $250.7B in 2026, with a net income margin of 32.75%, though profit margins have declined from 2022 peaks. Analyst sentiment is mixed, with 26.7% buy ratings but a majority hold consensus.
The outlook for UMC is cautiously optimistic, driven by AI expansion and solid profitability, but risks include competitive pressures and margin compression. Near-term price action hinges on breaking resistance at $19, with support at $18. Institutional activity shows mixed positioning, reflecting uncertainty over execution amid capital expenditure increases.
Trailing returns across standard periods
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →